High-end drugs have always been the focus of research and development in the medical field. With the support of various national policies, the research and development of innovative drugs in my country is on the rise. However, the packaging of high-end drugs has always been a concern in the industry. Material properties such as polypropylene and polyethylene are not suitable for high-end drugs, but those with high transparency, corrosion resistance, good storage performance, easy disinfection and sterilization, and low price Due to the shortcomings of protein adsorption, glass bottles greatly reduce the capacity of high-end drugs. Is there a material that combines the advantages of glass bottles with the properties of low protein adsorption?
In fact, a material with low protein adsorption properties is gradually becoming the exclusive packaging for biological products and anti-tumor drugs, that is, COP vials. COP raw material is developed and produced by Japan Zeon Company, used for medical optical components and high-end pharmaceutical packaging materials, with high transparency, excellent low protein adsorption, low birefringence, good water vapor air tightness, and compatibility with pharmaceuticals. It has the advantages of no peeling off, no discoloration after radiation, high temperature sterilization, etc. It can also be used as a container for biological products and organic solutions that need to be frozen.
COP vials are mainly used for high value-added drugs, such as lymphocyte antigens, hormone drugs, anesthesia drugs, drugs with a pH value greater than 9, and projects with accurate dosage requirements. Although the price of COP bottle is slightly higher than that of glass bottle, the drugs in its application field generally have higher prices, and the low protein adsorption characteristics of COP can greatly improve the use value of drugs and save some pharmaceutical costs for pharmaceutical companies. Said that it is more suitable for high-end drugs to choose COP bottles.
Everything is constantly developing and changing. Pharmaceutical companies must learn to look at problems with a developmental perspective. They should not only see the high price of COP bottles, but also pay attention to the value brought by their application in the market. At present, some domestic pharmaceutical companies have been at the forefront of the industry. For example, a certain original research drug of CSPC and the COP bottle produced by Xinfuda have passed the CDE related review in 2018 (registration number: B20180001378), Mass production of the drug is just around the corner. It is believed that with the continuous deepening of innovative drug research and development in my country, the market of COP bottles will also usher in a rapid development.
没有评论:
发表评论